PharmacoEconomics

Acknowledgement

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?

Livio Garattini, Francesca Ghislandi, Milene Rangel Da Costa

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease

Zobair M. Younossi, Linda Henry

Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice

James F. O’Mahony, Anthony T. Newall, Joost van Rosmalen

Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence

Christina Giannopoulou, Eleftherios Sideris, Ros Wade, Thirimon Moe-Byrne, Alison Eastwood, Claire McKenna

Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making?

Jonathan Karnon, Andrew Partington

Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment

Liesbet van de Wetering, Job van Exel, Ana Bobinac, Werner B. F. Brouwer

Cost Effectiveness of Falls and Injury Prevention Strategies for Older Adults Living in Residential Aged Care Facilities

Jody L. Church, Marion R. Haas, Stephen Goodall

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland

Florian S. Gutzwiller, Alena M. Pfeil, Zanfina Ademi, Patricia R. Blank, Peter G. Braunhofer, Thomas D. Szucs, Matthias Schwenkglenks